Upadacitinib 45mg ER Tablets$118.00
1–9 boxes
$118.00 each
10–24 boxes
8% off
25+ boxes
10% off
Upadacitinib 45mg ER Tablets
SKU GME530Product Introduction
Upadacitinib 45mg ER tablet is an extended-release JAK inhibitor used for induction treatment of active ulcerative colitis or Crohn disease in eligible adults. After induction, treatment changes to a lower maintenance strength.
How to use
Swallow the extended-release tablet whole with water at a consistent time, with or without food. Do not crush, split or chew it. Avoid grapefruit and grapefruit juice, which can increase upadacitinib exposure.
How it works
Upadacitinib inhibits JAK-mediated cytokine signaling, reducing immune-driven inflammation in selected inflammatory diseases.
Side effects
Possible effects include upper respiratory infection, nausea, acne, headache, fever, cough, herpes zoster, raised cholesterol, and lab changes. Serious concerns include severe infection, TB, malignancy, MACE, thrombosis, GI perforation, liver injury, low blood counts, and allergic reaction.
Important information
Tell your doctor about infection symptoms, tuberculosis or hepatitis, heart or blood-vessel risk, smoking, cancer, blood clots or diverticulitis. Mention pregnancy, breastfeeding, vaccination plans, medicines affecting CYP3A4 and other immunosuppressants. Screening and monitoring include blood counts, liver tests and cholesterol levels.
Uses
- Induction treatment of eligible adults with moderately to severely active ulcerative colitis or Crohn disease.
Benefits
Can reduce inflammation, symptoms, and flares in eligible patients after appropriate screening and monitoring.
What is Upadacitinib 45mg used for?
The 45mg regimen is an initial bowel-disease treatment: the reference regimen is eight weeks for ulcerative colitis or twelve weeks for Crohn disease, followed by a lower maintenance strength. Kidney, liver and interaction-related adjustments can change the regimen.
Why are screening tests needed?
Testing helps identify infection, blood-count, liver, lipid, and safety risks before and during treatment.
Can tablets be split?
No. Splitting, crushing or chewing disrupts the extended-release tablet. A visible tablet remnant in stool does not by itself mean the medicine has failed, but repeated intact remnants should be reported.
What infection symptoms matter?
Fever, persistent cough, shingles rash, painful urination, wounds, or feeling very unwell should be reported promptly.
Are live vaccines allowed?
Live vaccines are generally avoided during therapy; vaccination should be reviewed before starting.
JAK inhibitor: a medicine that reduces signalling through Janus kinase pathways. Cytokine: a protein involved in immune communication. Induction: the initial phase aiming to bring active disease under control. Maintenance: ongoing treatment to preserve response. Herpes zoster: shingles caused by reactivation of varicella-zoster virus.; AR: Upadacitinib 45mg أقراص; FR: Upadacitinib 45mg comprimé; PT: Upadacitinib 45mg comprimido; ES: Upadacitinib 45mg tableta; RU: Upadacitinib 45mg таблетки; ID: Upadacitinib 45mg tablet; VI: Upadacitinib 45mg viên nén; MS: Upadacitinib 45mg tablet; TL: Upadacitinib 45mg tableta; ZH-SG: Upadacitinib 45mg 片剂